Skip to main content
SpringerLink
Log in
Book cover

The Tumor Immunoenvironment pp 549–565Cite as

Cancer Immunotherapy: Overview in Brief

  • Chapter
  • First Online:

Abstract

Within the recent years, the indispensable contribution of immune responses and inflammation during control and progression of malignant diseases has become apparent and a focus of scientific investigation, revealing new insights into the highly complex cellular and molecular mechanisms determining the fate of tumor-driven and tumor specific immune responses in individual patients. On this basis, cancer immunotherapy has been provided with a broad variety of novel tool and therapeutic strategies that not only allow inducing stronger and better T cell responses but that also allow interfering with regulatory mechanisms within the tumor microenvironment. Exploiting these approaches, cancer immunotherapy has recently provided proof of clinical efficacy for a number of different therapeutic approaches which pave the way towards broader exploration of more advanced strategies combining systemic and local immunologic interventions on different mechanistic levels. Here, respective major strategies of cancer immunotherapy and their future perspectives are introduced and discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA (1997) Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 158:3947–3958

    PubMed  CAS  Google Scholar 

  • Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA (2001) Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol 13:897–908

    Article  PubMed  CAS  Google Scholar 

  • Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK et al (2002) A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci USA 99:13020–13025

    Article  PubMed  CAS  Google Scholar 

  • Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR et al (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601

    PubMed  CAS  Google Scholar 

  • Appay V, Douek DC, Price DA (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14:623–628

    Article  PubMed  CAS  Google Scholar 

  • Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252

    Article  PubMed  CAS  Google Scholar 

  • Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974–977

    Article  PubMed  CAS  Google Scholar 

  • Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A et al (2010) Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Med 16:565–570

    Article  PubMed  CAS  Google Scholar 

  • Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Investig 118:294–305

    Article  PubMed  CAS  Google Scholar 

  • Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC et al (2009) Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114:2417–2426

    Article  PubMed  CAS  Google Scholar 

  • Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G et al (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110:2838–2845

    Article  PubMed  CAS  Google Scholar 

  • Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y et al (2009) Antigen-specific tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Investig 119:3311–3321

    PubMed  CAS  Google Scholar 

  • Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196:1627–1638

    Article  PubMed  CAS  Google Scholar 

  • Cawthon AG, Alexander-Miller MA (2002) Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J Immunol 169:3492–3498

    PubMed  CAS  Google Scholar 

  • Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238

    Article  PubMed  CAS  Google Scholar 

  • Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B et al (2009) Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 69:8420–8428

    Article  PubMed  CAS  Google Scholar 

  • Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83–117

    Article  PubMed  CAS  Google Scholar 

  • Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J et al (2007) IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 37:1678–1690

    Article  PubMed  CAS  Google Scholar 

  • Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC et al (2010) CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res: Official J Am Assoc Cancer Res 16:6122–6131

    Article  CAS  Google Scholar 

  • Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J et al (2012) Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain:J Neurol 135:1042–1054

    Article  Google Scholar 

  • Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK et al (2008) Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res 68:3467–3475

    Article  PubMed  CAS  Google Scholar 

  • Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC (1996) Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 157:1406–1414

    PubMed  CAS  Google Scholar 

  • Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res: Official J Am Assoc Cancer Res 13:5256–5261

    Article  CAS  Google Scholar 

  • Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964

    Article  PubMed  CAS  Google Scholar 

  • Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z et al (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15:808–813

    Article  PubMed  CAS  Google Scholar 

  • Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J et al (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol, Immunother: CII 61:353–362

    Article  CAS  Google Scholar 

  • Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W et al (2009) Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol, Immunother: CII 58:1329–1336

    Article  CAS  Google Scholar 

  • Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32:593–604

    Article  PubMed  CAS  Google Scholar 

  • Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S et al (2011) Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72:1631–1638

    Article  PubMed  CAS  Google Scholar 

  • Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A et al (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71:5670–5677

    Article  PubMed  CAS  Google Scholar 

  • Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C et al (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69:3077–3085

    Article  PubMed  CAS  Google Scholar 

  • Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M et al (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194:769–779

    Article  PubMed  CAS  Google Scholar 

  • Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z et al (2009) Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 106:17469–17474

    Article  PubMed  CAS  Google Scholar 

  • Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J (2005) Multiple costimulatory modalities enhance CTL avidity. J Immunol 174:5994–6004

    PubMed  CAS  Google Scholar 

  • Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM et al (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res: Official J Am Assoc Cancer Res 16:5067–5078

    Article  CAS  Google Scholar 

  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010a) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 363:411–422

    Article  PubMed  CAS  Google Scholar 

  • Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M et al (2010b) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 28:1099–1105

    Article  CAS  Google Scholar 

  • Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, der Meer Berends-van DM, Vloon AP et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New Engl J Med 361:1838–1847

    Article  PubMed  CAS  Google Scholar 

  • Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res Official J Am Assoc Cancer Res 12:6106–6115

    Article  CAS  Google Scholar 

  • Khazaie K, Bonertz A, Beckhove P (2009) Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 21:524–530

    Article  PubMed  CAS  Google Scholar 

  • Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol: Official J Am Soc Clin Oncol 24:e20–e22

    Article  Google Scholar 

  • Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T et al (2003) Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 198:361–367

    Article  PubMed  CAS  Google Scholar 

  • Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102:16013–16018

    Article  PubMed  CAS  Google Scholar 

  • Li LP, Lampert JC, Chen X, Leitao C, Popovic J, Muller W et al (2010) Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 16:1029–1034

    Article  PubMed  CAS  Google Scholar 

  • Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162–179

    Article  PubMed  CAS  Google Scholar 

  • Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K et al (2002) Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4–1BB. Nat Biotechnol 20:143–148

    Article  PubMed  CAS  Google Scholar 

  • Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29:372–383

    Article  PubMed  CAS  Google Scholar 

  • Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W et al (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 108:17111–17116

    Article  PubMed  CAS  Google Scholar 

  • Moore KW, Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) de Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765

    Article  PubMed  CAS  Google Scholar 

  • Palucka K, Ueno H, Roberts L, Fay J, Banchereau J (2010) Dendritic cells: are they clinically relevant? Cancer J 16:318–324

    Article  PubMed  CAS  Google Scholar 

  • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP (2009) Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:1717–1725

    Article  PubMed  CAS  Google Scholar 

  • Powell E, Chow LQ (2008) BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer. Expert Rev Respir Med 2:37–45

    Article  PubMed  CAS  Google Scholar 

  • Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X et al (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207:637–650

    Article  PubMed  CAS  Google Scholar 

  • Rammensee HG (2006) Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer. Immunol Cell Biol 84:290–294

    Article  PubMed  CAS  Google Scholar 

  • Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281

    Article  PubMed  CAS  Google Scholar 

  • Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E et al (2007) Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 110:1924–1932

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299–308

    Article  PubMed  CAS  Google Scholar 

  • Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP et al (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol: Official J Am Soc Clin Oncol 29:2787–2794

    Article  CAS  Google Scholar 

  • Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. New Engl J Med 364:2119–2127

    Article  PubMed  CAS  Google Scholar 

  • Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835–1837

    Article  PubMed  CAS  Google Scholar 

  • Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR et al (2008) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 205:1701–1714

    Article  PubMed  CAS  Google Scholar 

  • Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21:685–711

    Article  PubMed  CAS  Google Scholar 

  • Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD et al (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515–520

    Article  PubMed  CAS  Google Scholar 

  • Thakur A, Lum LG (2010) Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther 12:340–349

    PubMed  CAS  Google Scholar 

  • Thomas DA, Massague J (2005) TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369–380

    Article  PubMed  CAS  Google Scholar 

  • Uckert W, Schumacher TN (2009) TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol, Immunother: CII 58:809–822

    Article  CAS  Google Scholar 

  • Voss RH, Thomas S, Pfirschke C, Hauptrock B, Klobuch S, Kuball J et al (2010) Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. Blood 115:5154–5163

    Article  PubMed  CAS  Google Scholar 

  • Wang RF, Rosenberg SA (1996) Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J Leukoc Biol 60:296–309

    PubMed  CAS  Google Scholar 

  • Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68

    Article  PubMed  CAS  Google Scholar 

  • Wilde S, Geiger C, Milosevic S, Mosetter B, Eichenlaub S, Schendel DJ (2012) Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: a three phase experimental procedure. Oncoimmunology 1:129–140

    Article  PubMed  Google Scholar 

  • Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23–35

    Article  PubMed  CAS  Google Scholar 

  • Yewdell JW, Haeryfar SM (2005) Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 23:651–682

    Article  PubMed  CAS  Google Scholar 

  • Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF et al (2011) Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 108:16723–16728

    Article  PubMed  CAS  Google Scholar 

  • Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X et al (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183:5563–5574

    Article  PubMed  CAS  Google Scholar 

  • Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM et al (2010) Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Investig 120:607–616

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Translational Immunology Division, German Cancer Research Center and National Center of Tumor Diseases, Heidelberg, INF 460, Heidelberg, 69120, Germany

    Philipp Beckhove

Authors
  1. Philipp Beckhove
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Beckhove .

Editor information

Editors and Affiliations

  1. Department of Pathology, University of Pittsburgh Medical Center, 3550 Terrace Street Scaife Hal, Pittsburgh, 15213, Pennsylvania, USA

    Michael R. Shurin

  2. , Clinical Cooperation Unit Dermato-Oncolo, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, 69120, Germany

    Viktor Umansky

  3. , SAIC-Frederick, Inc., National Cancer Institute at Frederick, Post Office B, Frederick, 21702, Maryland, USA

    Anatoli Malyguine

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Beckhove, P. (2013). Cancer Immunotherapy: Overview in Brief. In: Shurin, M., Umansky, V., Malyguine, A. (eds) The Tumor Immunoenvironment. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6217-6_23

Download citation

Publish with us

Policies and ethics

Search

Navigation